Volition logo logo
volition-nets-7
logo-nets

Our Nu.Q® NETs assay detects diseases associated with NETosis, such as sepsis.

Nu.Q® NETs

Overview

Rapid detection of sepsis is vital.

Sepsis is the number one cause of death in hospitals worldwide. It kills an estimated 11 million people a year, which is more than cancer or coronary disease. In 2017, there were an estimated 49 million cases resulting in an estimated 11 million deaths. Over half of all cases occur among children, accounting for 2.9 million deaths in under-fives. Just under half of all survivors are left with psychological and/or physical effects.

Sepsis, also known as ‘blood poisoning’, is hard to identify. Initial symptoms of sepsis are difficult to distinguish from most infections and there is currently a lack of tests to diagnose it symptomatically. Without prompt treatment, it can lead to multiple organ failure and death.

Early detection and treatment of sepsis has the potential to improve survival – and improve the quality of life of survivors.  Imagine if a simple blood test could help diagnose sepsis and identify those patients more likely to deteriorate.

Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failureRead our key clinical paper

Our Nu.Q® NETs assay detects diseases associated with NETosis, such as sepsis. It has the potential to help doctors accurately diagnose disease and could also help predict disease severity, measure response to treatment and monitor disease progression.

Nu.Q® NETs is a clinically meaningful, biologically specific marker of NETosis, with actionable potential in defined patient subgroups.

0 m

Estimated 11 million deaths from sepsis worldwide each year

0 %

Risk of death increases by 7.6% for every hour of treatment delay.

The science of nets

Understanding NETs and NETosis – a recent breakthrough in medical science

volition-nets-3
Introducing Nu.Q® NETs

The immune system is comprised of many different types of white blood cell with different functions. The most abundant cells are neutrophils, which serve as the first line of defense. When they detect bacteria, viruses or fungi, these cells produce Neutrophil Extracellular Traps (NETs) – sticky webs made of long strings of nucleosomes that stop the threat from spreading around the body. This unique form of cell death is called NETosis. NETs released into the blood stream, contain nucleosomes, which can be detected by our Nu.Q® NETs assay – the only analytically validated assay to quantify the level of NETs.

Although NETs play a critical role in our normal immune response, elevated levels of NETs are a complicating factor associated with poor patient outcomes in sepsis, cancer, and a range of other diseases.

Learn about NETs, NETosis and Nu.Q® NETs: infographicLearn more about NETosis

Our Solution

Introducing Nu.Q® NETs.

Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis. Our assay can be used to identify patients with clinically relevant elevated levels of circulating NETs and enable physicians to rapidly treat these patients.

Chromosomes and NETs are made of nucleosomes, and NETs play a pivotal role in endothelial damage and the formation of microthrombi and resultant multiorgan failure.

Our Nu.Q® NETs is the only analytically validated assay to quantify the level of NETs. It is platform agnostic so it can be adapted to any workflow/clinical setting – including central lab and point of care.

Nu.Q® NETs will support clinical decision-making, enabling physicians to act quickly, improving patient outcomes and patient management.

It is registered for use in Europe in an automated ChLIA (Chemiluminescence immunoassay) format.

NETosis graphic Nov 2023
icon-microscope-blue

The only analytically validated assay to quantify levels of NETs

 

checklist

Associated with:
– presence of sepsis
– the severity of organ dysfunction
– a hyperinflammatory host response

icon-computer-blue

Patients with:
– acute kidney injury (AKI)
– disseminated intravascular coagulation (DIC)
– acute respiratory distress syndrome (ARDS)

exhibit significantly higher Nu.Q H3.1 levels

 

Use cases

Use cases – key findings to date

Volition_231018_1541

Related Resource

nuq-cover

Nu.Q® NETs brochure

Media & Downloads

Collaboration

Working together.

We are working with teams at several major hospitals across Europe, undertaking studies to test our technology as a diagnostic aid for sepsis, to monitor disease progression and treatment response.

logo-nets

Who: Large-scale study being undertaken in collaboration with Amsterdam UMC, a leading medical center, and led by Dr Lieuwe Bos.

About: A retrospective analysis of 4,000+ samples, prospectively collected from 1,700+ intensive care patients, to assess the potential value of Nu.Q® NETs assay to diagnose and monitor patients at risk of sepsis. Results presented at ISICEM 2025, peer-reviewed paper published in Critical Care, BMC, Part of Springer Nature

Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failureDownload the paper
volition-nets-8
logo-nets

Who: Large scale study undertaken in collaboration with German SepNet Study Group, led by Professor Michael Bauer, Chief Executive Director of the Center for Sepsis Control and Care,  Jena University Hospital.

About: A retrospective analysis of 1000 samples, prospectively collected from intensive care patients, to assess the potential value of Nu.Q® NETs assay to diagnose and monitor patients at risk of sepsis.

Next steps:  Results published at ESICM 2024, manuscript submitted for peer review and publication. 

Read study
volition-nets-3
logo-nets

Who: RECORDS study (Rapid recognition of Corticosteroid Resistant or sensitive Sepsis) currently being led by Professor Djillali Annane, France.

About: Our Nu.Q® NETs assay is being used as part of RHU RECORDS – a 1,500-patient study – to help identify eligible patients for corticosteroid therapy in the management of sepsis, and help establish decision-making thresholds. Nu.Q® NETs will also be used in conjunction with a point-of-care device to assess critical care requirements.

Next Steps: Interim analysis presented at ISICEM 2025, study due to be completed in 2025.

NETs lab3
santersus

Who: Santersus AG

About: We are working with Santersus AG, which is developing “NucleoCapture”, a transformational technology that cleanses blood of NETs as a sepsis treatment. They used Nu.Q® NETs within an animal study to measure treatment response and have moved to their first human trial, with results due shortly.

Find out more
NETs lab4
HCL

Who: Hospice Civil de Lyon, France

About: We worked with Hospices Civil de Lyon to measure nucleosome levels using the Nu.Q® NETs assay in septic shock patients. The study included 151 septic shock patients and demonstrated an association with mortality.

Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock.Read paper
NETs lab1
icon-microscope-blue

Detect NETosis

 

icon-computer-blue

Predict disease severity and support risk stratification

 

icon-clock-blue

Monitor disease progression

 

testimonial
I believe that using the Nu.Q® NETs test to measure elevated H3.1 nucleosome levels as a “treatable trait” in sepsis management could be a game changer in modifying a patient's trajectory. Introducing Nu.Q® NETs into hospitals could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors.
Professor Djillali Annane
Professor of Medicine at University Paris Saclay-UVSQ
Product Resources

Brochures & Clinical Papers

Golden retriever 4

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assis…

Press Releases
Thumbnails for website

Quantification of H3.1-nucleosomes using a chemiluminescent …

Poster & Publications
Thumbnails for website

Plasma H3.1 nucleosomes as biomarkers of infection, inflamma…

Poster & Publications
Review article thumbnail 2

“The NET effect”: Neutrophil extracellular traps—a potential…

Poster & Publications
escim symposium 2024 featured image

Symposium 2024 report: ‘Sepsis – a brighter hope…

Media & Downloads
AOIC featured

Association of pronounced elevation of NET formation and nuc…

Poster & Publications
Thumbnails for website

Plasma H3.1 nucleosomes as biomarkers of infection, inflamma…

Poster & Publications
nuq-cover

Nu.Q® NETs brochure

Media & Downloads
Volition